Nasdaq

Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS

CHARLOTTESVILLE, Va., May 05, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for ...
Business Insider

Diffusion Pharmaceuticals Announces Pre-IND Submission to the FDA of Design for TSC Trials to Treat Acute Respiratory Distress Syndrome in COVID-19

• Program to focus on enhanced blood oxygenation and reduction in patient progression to Intensive Care Units • Patient enrollment planned for both the U.S. and Eastern Europe CHARLOTTESVILLE, Va., ...
Nasdaq

Diffusion Pharmaceuticals Appoints Jane H. Hollingsworth to its Board of Directors

CHARLOTTESVILLE, Va., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a biotechnology company developing new treatments for ...